Anti-obesity drugs are pharmacological agents that reduce or control weight. These drugs alter one of the fundamental processes of the human body, weight regulation, by altering either appetite, or absorption of calories. The main treatment modalities for overweight and obese individuals remain dieting and physical exercise.

The report analysts forecast the Global Anti-obesity Drugs market to grow at a CAGR of 41.45 percent over the period 2013-2022.

The global Anti-obesity Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Anti-obesity Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Anti-obesity Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Anti-obesity Drugs in these regions.

This research report categorizes the global Anti-obesity Drugs market by top players/brands, region, type and end user. This report also studies the global Anti-obesity Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:

- Merck
- Novo Nordisk
- Pfizer
- Arena Pharmaceuticals
- Roche
- GlaxoSmithKline
- Orexigen Therapeutics
- Vivus
- Amylin
- Alnylam
- Boehringer Ingelheim
- Eisai

The study objectives of this report are:
To study and analyze the global Anti-obesity Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Anti-obesity Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Anti-obesity Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Anti-obesity Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Anti-obesity Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Anti-obesity Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Study Coverage

1.1 Anti-obesity Drugs Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
   1.4.1 Global Anti-obesity Drugs Market Size Growth Rate by Product
   1.4.2 Peripherally Acting Anti-obesity Drugs
   1.4.3 Centrally Acting Anti-obesity Drugs
1.5 Market by End User
   1.5.1 Global Anti-obesity Drugs Market Size Growth Rate by End User
   1.5.2 Kids
   1.5.3 Adults
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary

2.1 Global Anti-obesity Drugs Market Size
   2.1.1 Global Anti-obesity Drugs Revenue 2014-2025
   2.1.2 Global Anti-obesity Drugs Sales 2014-2025
2.2 Anti-obesity Drugs Growth Rate by Regions
   2.2.1 Global Anti-obesity Drugs Sales by Regions
   2.2.2 Global Anti-obesity Drugs Revenue by Regions

3 Breakdown Data by Manufacturers

3.1 Anti-obesity Drugs Sales by Manufacturers
   3.1.1 Anti-obesity Drugs Sales by Manufacturers
   3.1.2 Anti-obesity Drugs Sales Market Share by Manufacturers
   3.1.3 Global Anti-obesity Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Anti-obesity Drugs Revenue by Manufacturers
   3.2.1 Anti-obesity Drugs Revenue by Manufacturers (2014-2019)
   3.2.2 Anti-obesity Drugs Revenue Share by Manufacturers (2014-2019)
3.3 Anti-obesity Drugs Price by Manufacturers
3.4 Anti-obesity Drugs Manufacturing Base Distribution, Product Types
   3.4.1 Anti-obesity Drugs Manufacturers Manufacturing Base Distribution, Headquarters
   3.4.2 Manufacturers Anti-obesity Drugs Product Type
   3.4.3 Date of International Manufacturers Enter into Anti-obesity Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

4.1 Global Anti-obesity Drugs Sales by Product
4.2 Global Anti-obesity Drugs Revenue by Product
4.3 Anti-obesity Drugs Price by Product

5 Breakdown Data by End User

5.1 Overview
5.2 Global Anti-obesity Drugs by End User

6 North America

6.1 North America Anti-obesity Drugs by Countries
   6.1.1 North America Anti-obesity Drugs Sales by Countries
   6.1.2 North America Anti-obesity Drugs Revenue by Countries
   6.1.3 United States
   6.1.4 Canada
   6.1.5 Mexico
6.2 North America Anti-obesity Drugs by Product
6.3 North America Anti-obesity Drugs by End User

7 Europe

7.1 Europe Anti-obesity Drugs by Countries
   7.1.1 Europe Anti-obesity Drugs Sales by Countries
   7.1.2 Europe Anti-obesity Drugs Revenue by Countries
8 Asia Pacific

8.1 Asia Pacific Anti-obesity Drugs by Countries
  8.1.1 Asia Pacific Anti-obesity Drugs Sales by Countries
  8.1.2 Asia Pacific Anti-obesity Drugs Revenue by Countries
  8.1.3 China
  8.1.4 Japan
  8.1.5 Korea
  8.1.6 India
  8.1.7 Australia
  8.1.8 Indonesia
  8.1.9 Malaysia
  8.1.10 Philippines
  8.1.11 Thailand
  8.1.12 Vietnam
  8.1.13 Singapore

8.2 Asia Pacific Anti-obesity Drugs by Product

8.3 Asia Pacific Anti-obesity Drugs by End User

9 Central & South America

9.1 Central & South America Anti-obesity Drugs by Countries
  9.1.1 Central & South America Anti-obesity Drugs Sales by Countries
  9.1.2 Central & South America Anti-obesity Drugs Revenue by Countries
  9.1.3 Brazil

9.2 Central & South America Anti-obesity Drugs by Product

9.3 Central & South America Anti-obesity Drugs by End User

10 Middle East and Africa

10.1 Middle East and Africa Anti-obesity Drugs by Countries
  10.1.1 Middle East and Africa Anti-obesity Drugs Sales by Countries
  10.1.2 Middle East and Africa Anti-obesity Drugs Revenue by Countries
  10.1.3 GCC Countries
  10.1.4 Turkey
  10.1.5 Egypt
  10.1.6 South Africa

10.2 Middle East and Africa Anti-obesity Drugs by Product

10.3 Middle East and Africa Anti-obesity Drugs by End User

11 Company Profiles

11.1 Merck
  11.1.1 Merck Company Details
  11.1.2 Company Business Overview
  11.1.3 Merck Anti-obesity Drugs Sales, Revenue and Gross Margin (2014-2019)
  11.1.4 Merck Anti-obesity Drugs Products Offered
  11.1.5 Merck Recent Development

11.2 Novo Nordisk
  11.2.1 Novo Nordisk Company Details
  11.2.2 Company Business Overview
  11.2.3 Novo Nordisk Anti-obesity Drugs Sales, Revenue and Gross Margin (2014-2019)
  11.2.4 Novo Nordisk Anti-obesity Drugs Products Offered
  11.2.5 Novo Nordisk Recent Development

11.3 Pfizer
  11.3.1 Pfizer Company Details
  11.3.2 Company Business Overview
  11.3.3 Pfizer Anti-obesity Drugs Sales, Revenue and Gross Margin (2014-2019)
  11.3.4 Pfizer Anti-obesity Drugs Products Offered
  11.3.5 Pfizer Recent Development

11.4 Arena Pharmaceuticals
  11.4.1 Arena Pharmaceuticals Company Details
  11.4.2 Company Business Overview
  11.4.3 Arena Pharmaceuticals Anti-obesity Drugs Sales, Revenue and Gross Margin (2014-2019)
  11.4.4 Arena Pharmaceuticals Anti-obesity Drugs Products Offered
  11.4.5 Arena Pharmaceuticals Recent Development

11.5 Roche
  11.5.1 Roche Company Details
  11.5.2 Company Business Overview
  11.5.3 Roche Anti-obesity Drugs Sales, Revenue and Gross Margin (2014-2019)
  11.5.4 Roche Anti-obesity Drugs Products Offered
  11.5.5 Roche Recent Development

11.6 GlaxoSmithKline
  11.6.1 GlaxoSmithKline Company Details
  11.6.2 Company Business Overview
  11.6.3 GlaxoSmithKline Anti-obesity Drugs Sales, Revenue and Gross Margin (2014-2019)
  11.6.4 GlaxoSmithKline Anti-obesity Drugs Products Offered
  11.6.5 GlaxoSmithKline Recent Development

11.7 Orexigen Therapeutics
  11.7.1 Orexigen Therapeutics Company Details
  11.7.2 Company Business Overview
  11.7.3 Orexigen Therapeutics Anti-obesity Drugs Sales, Revenue and Gross Margin (2014-2019)
  11.7.4 Orexigen Therapeutics Anti-obesity Drugs Products Offered
11.7.5 Orexigen Therapeutics Recent Development

11.8 Vivus
- 11.8.1 Vivus Company Details
- 11.8.2 Company Business Overview
- 11.8.4 Vivus Anti-obesity Drugs Products Offered
- 11.8.5 Vivus Recent Development

11.9 Amylin
- 11.9.1 Amylin Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Amylin Anti-obesity Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Amylin Anti-obesity Drugs Products Offered
- 11.9.5 Amylin Recent Development

11.10 Alizyme
- 11.10.1 Alizyme Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Alizyme Anti-obesity Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Alizyme Anti-obesity Drugs Products Offered
- 11.10.5 Alizyme Recent Development

11.11 Boehringer Ingelheim
11.12 Eisai

12 Future Forecast
- 12.1 Anti-obesity Drugs Market Forecast by Regions
  - 12.1.1 Global Anti-obesity Drugs Sales Forecast by Regions 2019-2025
  - 12.1.2 Global Anti-obesity Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Anti-obesity Drugs Market Forecast by Product
  - 12.2.1 Global Anti-obesity Drugs Sales Forecast by Product 2019-2025
  - 12.2.2 Global Anti-obesity Drugs Revenue Forecast by Product 2019-2025
- 12.3 Anti-obesity Drugs Market Forecast by End User
- 12.4 North America Anti-obesity Drugs Forecast
- 12.5 Europe Anti-obesity Drugs Forecast
- 12.6 Asia Pacific Anti-obesity Drugs Forecast
- 12.7 Central & South America Anti-obesity Drugs Forecast
- 12.8 Middle East and Africa Anti-obesity Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Anti-obesity Drugs Customers
- 14.3 Sales Channels Analysis
  - 14.3.1 Sales Channels
  - 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
- 16.1 Research Methodology
  - 16.1.1 Methodology/Research Approach
  - 16.1.2 Data Source
- 16.2 Author Details